恒瑞医药：子公司收到HRS-6257片临床试验批准通知书 国内尚无同靶点药物获批上市

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6257, a drug intended for postoperative analgesia, marking a significant step in its development pipeline [1] Group 1: Company Developments - Heng Rui Medicine's subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has been granted a Clinical Trial Approval Notice for HRS-6257 [1] - The drug is aimed at treating acute and chronic pain, with no similar target drugs approved in the domestic market [1] - The total research and development investment for the project has reached approximately 15.58 million yuan [1] Group 2: Regulatory and Market Context - The approval allows the company to conduct clinical trials, which must be completed and reviewed by the National Medical Products Administration before the drug can be manufactured and marketed [1]